A-796,260

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Trappist the monk (talk | contribs) at 11:52, 9 January 2014 (Fix CS1 deprecated date parameter errors (test) using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

A-796,260
Identifiers
  • 1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.233.198 Edit this at Wikidata
Chemical and physical data
FormulaC22H30N2O2
Molar mass354.485 g/mol g·mol−1
3D model (JSmol)
  • C4COCCN4CCn(c3ccccc13)cc1C(=O)C2C(C)(C)C2(C)C
  • InChI=1S/C22H30N2O2/c1-21(2)20(22(21,3)4)19(25)17-15-24(18-8-6-5-7-16(17)18)10-9-23-11-13-26-14-12-23/h5-8,15,20H,9-14H2,1-4H3 checkY
  • Key:ZCFHOMLAFTWDFM-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

A-796,260 is a drug developed by Abbott Laboratories that acts as a potent and selective cannabinoid CB2 receptor agonist. Replacing the aromatic 3-benzoyl or 3-naphthoyl group found in most indole derived cannabinoids with the 3-tetramethylcyclopropylmethanone group, imparts significant selectivity for CB2, and A-796,260 was found to be a highly selective CB2 agonist with little affinity for CB1, having a CB2 Ki of 4.6 nM vs 945 nM at CB1.[1] It has potent analgesic and anti-inflammatory actions in animal models, being especially effective in models of neuropathic pain, but without producing cannabis-like behavioral effects.[2]

See also

References

  1. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1021/jm901214q, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1021/jm901214q instead.
  2. ^ Yao BB; et al. (January 2008). "In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models". British Journal of Pharmacology. 153 (2): 390–401. doi:10.1038/sj.bjp.0707568. PMC 2219533. PMID 17994110. {{cite journal}}: Explicit use of et al. in: |author= (help)